GlaxoSmithKline and Vir Biotechnology Inc. stated on Thursday that they are looking for an expansion to the United States approval of their antibody-based COVID-19 treatment to include the option of intramuscular injection.
The drug in question, sotrovimab, was authorized for intravenous...
The United States government reached a deal to buy 600,000 doses of the antibody COVID-19 treatment developed by GlaxoSmithKline and Vir Biotechnology, the two companies confirmed on Tuesday.
The batch will be delivered in the first quarter of this year, the statement added, bringing...
GlaxoSmithKline plc confirmed on Tuesday that its COVID-19 therapy jointly developed with Vir Biotechnology is effective against the Omicron coronavirus mutation.
"Sotrovimab is the first monoclonal antibody to report preclinical data demonstrating activity against all tested SARS-CoV-2...
The United States government has signed a contract for a further 300,000 doses of GlaxoSmithKline's (GSK) sotrovimab COVID-19 antibody drug, according to a source quoted by the Wall Street Journal on Wednesday.
The deal is reportedly worth $651 million and brings the total order value...
Vir Biotechnology Inc. and GlaxoSmithKline plc (GSK) claimed on Monday that their coronavirus antibody treatment remains effective versus the COVID-19 strain initially detected in California.
Data obtained through new preclinical research hinted that the antibody treatment called VIR-7831...
Vir Biotechnology Inc. and GlaxoSmithKline plc (GSK) stated on Thursday that their coronavirus antibody treatment has shown 85% efficacy in curbing the number of deaths and hospitalizations in COVID patients at high risk of hospitalization.
While the two companies announced that the trial is...
GlaxoSmithKline plc and Vir Biotechnology Inc. have agreed to expand their joint research and development program to include new treatments for respiratory viruses.
Under the terms of the new deal, GSK will increase its equity investment in the California-based biotech firm by $120 million and...
Vir Biotechnology Inc. and GlaxoSmithKline plc revealed on Monday that the phase 2/3 study of their jointly developed coronavirus antibody treatment began last week.
VIR-7831 (or GSK4182136), which has been described by the companies as a "fully human" anti-coronavirus "monoclonal antibody,"...
GlaxoSmithKline plc (GSK) said on Monday it signed a partnership agreement with Vir Biotechnology, Inc. to work together on finding a treatment for the coronavirus.
"The collaboration will use Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new...
Vir Biotechnology's initial public offering pricing values the company at $2.2 billion, the company said in a press release as it announced that it priced its IPO at $20 per share. The company will offer over 7 million shares and hopes to raise $142.9 million.
The clinical-stage immunology company that...
This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.
